Hydrocortisone Phosphoric Acid

Summary

Hydrocortisone Phosphoric Acid (CHEMBL1641) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 442.4 Da · C21H31O8P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1641
Name	Hydrocortisone Phosphoric Acid
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	441407
ChEBI	CHEBI:68634
Molecular formula	C21H31O8P
Molecular weight	442.4
InChIKey	BGSOJVFOEQLVMH-VWUMJDOOSA-N

SMILES: C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)COP(=O)(O)O)O)C)O

IUPAC name: [2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethyl] dihydrogen phosphate

ChEBI definition: A steroid phosphate that is the 21-O-phospho derivative of cortisol.

Also known as: Hydrocortisone phosphate, SID50112718

Parent form; salt/anhydrous children: CHEMBL1200968

Patent coverage: 478 distinct patent families (1,666 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).